|Bid||0.0600 x N/A|
|Ask||0.0650 x N/A|
|Day's Range||0.0600 - 0.0650|
|52 Week Range||0.0300 - 0.1800|
|Beta (5Y Monthly)||5.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 05, 2019 - Apr. 08, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
TORONTO — Some of the most active companies traded Wednesday on the Toronto Stock Exchange:Toronto Stock Exchange (15,629.19, up 33.69 points.)The Toronto-Dominion Bank (TSX:TD). Financials. Up eight cents, or 0.13 per cent, to $60.30 on 21.8 million shares.StageZero Life Sciences Ltd. (TSX:SZLS). Health care. Up half a cent, or 9.09 per cent, to six cents on 9 million shares.St. Augustine Gold and Copper (TSX:SAU). Materials. Down 5.5 cents, or 39.29 per cent, to 8.5 cents on 8.3 million shares.Kinross Gold Corp. (TSX:K). Materials. Up 15 cents, or 1.48 per cent, to $10.26 on 6.1 million shares.B2Gold Corp. (TSX:BTO). Materials. Up 19 cents, or 2.4 per cent, to $8.12 on 5.7 million shares.The Bank of Nova Scotia. (TSX:BNS). Financials. Down 22 cents, or 0.4 per cent, to $54.73 on 5.3 million shares.Companies in the news:Transat AT (TSX:TRZ). Down five cents to $5.51. Air Transat is looking to reduce greenhouse gas emissions from its airplanes by using jet fuel made from kerosene in a process that captures carbon dioxide produced by large industrial emitters. The Montreal-based airline has signed an agreement with SAF+ Consortium, which is finalizing the fabrication of a pilot plant in Montreal to make the kerosene. The kerosene is then converted to synthetic jet fuel which is estimated to have an 80 per cent lower carbon footprint than conventional jet fuel. Air Transat says it will buy a significant portion of the future sustainable aviation fuel (SAF) production. SAF + Consortium chief technical officer, Alexandru Iordan, says demand for sustainable aviation fuel will almost double annually for the next 30 years.DavidsTea — DavidsTea is seeking court protection from creditors so it can continue operating while it restructures and plans to close a significant number of its stores. The Montreal-based company said Wednesday it will seek an order in Quebec Superior Court to allow it to restructure under the Companies' Creditors Arrangement Act. It also plans to seek similar orders for its U.S. subsidiary under Chapter 15 of the U.S. Bankruptcy Code. The company said during the restructuring process it plans to continue operating online through davidstea.com and its wholesale distribution channel, which supplies grocery stores and pharmacies. The chain's stores have been shut since March 17 due to the COVID-19 pandemic. It had warned in mid-June that it hadn't paid rent on any of its stores for April, May and June and that it may seek a formal restructuring.This report by The Canadian Press was first published July 8, 2020.The Canadian Press
TORONTO, ON / ACCESSWIRE / July 2, 2020 / StageZero Life Sciences (TSX:SZLS) (''StageZero Life Sciences'' or the ''Company'') today announced a corporate update on its business. The Company was pleased ...
TORONTO, ON / ACCESSWIRE / June 29, 2020 / StageZero Life Sciences Ltd. (SZLS.TO) (the "Company") is pleased to announce that is has closed its previously announced public offering of 66,176,100 units of the Company (the "Units") at a price of $0.07 per Unit (the "Offering Price") for aggregate gross proceeds of $4,632,327 (the "Offering"). The Offering was made pursuant to an agency agreement effective June 22, 2020 with Echelon Wealth Partners Inc. and Clarus Securities Inc. (collectively, the "Agents"). Each Unit was comprised of one common share of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").
TORONTO , June 29, 2020 /CNW/ - The following issues have been halted by IIROC: Company: StageZero Life Sciences Ltd. Warrants TSX Symbol: SZLS.WT Reason: Pending Closing Halt Time (ET): 8:00 AM IIROC ...
The Toronto Stock Exchange has conditionally approved the listing of the common shares (the "Shares") partially comprising the units (the "Units") offered by the prospectus, the Shares issuable upon exercise of the warrants (the "Warrants") partially comprising the Units, the shares issuable upon exercise of broker warrants and compensation warrants granted to the agents for the prospectus offering. Listing is subject to the Company fulfilling all of the requirements of the Toronto Stock Exchange on or before August 31, 2020. The Toronto Stock Exchange has conditionally approved the listing of the Warrants.
TORONTO, CANADA / ACCESSWIRE / June 18, 2020 / StageZero Life Sciences Ltd. (TSX:SZLS) (" StageZero ", or the " Company ") has filed its amended and restated management discussion and ...
TORONTO , June 11, 2020 /CNW/ - https://www.youtube.com/watch?v=QifanjnKxWo The C-Suite At the Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange ...
TORONTO , June 2, 2020 /CNW/ - Trading resumes in: Company: StageZero Life Sciences Ltd. TSX Symbol: SZLS (All Issues) Resumption (ET): 3:15:00 PM IIROC can make a decision to impose a temporary suspension ...
Each Unit will be offered at a price of $0.07 per Unit (the "Offering Price") and will be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $0.09 for a period of 36 months following the closing date of the Offering.
Each Unit will consist of one common share in the capital of the Company (each, a "Common Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant"). The Offering will be conducted by Echelon Wealth Partners Inc. ("Echelon") and Clarus Securities Inc. ("Clarus", and collectively with Echelon, the "Agents") as co-lead Agents and joint bookrunners.
TORONTO, ON / ACCESSWIRE / June 1 , 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") today announced operational results for the three month period ended ...
LOS ANGELES, CA / ACCESSWIRE / May 28, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with James Howard-Tripp, Chairman and CEO of StageZero ...
TORONTO, ON / ACCESSWIRE / May 20, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") today announced that due to the disruption caused by COVID-19 and its ...
TORONTO, ON / ACCESSWIRE / May 20, 2020 / StageZero Life Sciences (SZLS.TO) (''StageZero'' or the ''Company'') today announced operational and financial results for the three-month and twelve-month periods ended December 31, 2019 and provided a progress update on its business. Full Year 2019 saw consolidation of the business under the StageZero Life Sciences banner and the building out of key commercialization infrastructure that will prove critical in 2020.
StageZero Life Sciences will offer, via UDoTest's online platform, PCR testing for the live virus, as well as antibody tests to test for past infection. "This is a highly coordinated effort to deliver COVID-19 testing more efficiently around the country," says James Howard-Tripp, Chairman and CEO of StageZero Life Sciences.
In the news release, "StageZero Announces Fourth Quarter 2019 Results and Year End Investor Call", issued May 13, 2020 by StageZero Life Sciences Limited over Accesswire, we are advised by the ...
TORONTO, ON / ACCESSWIRE / May 13, 2020 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its Fourth Quarter 2019 operational ...
TORONTO, ON / ACCESSWIRE / May 12, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") today announced that the Convertible Security Funding Agreement for ...
TORONTO, ON / ACCESSWIRE / May 4, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") today announced an enhanced relationship with Phleb-Finders. Phleb-Finders ...
The Company offers the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved. The Company will approach antibody testing as a two-step process.
The Company will offer both the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved. The Company is first directing its testing to healthcare groups and frontline workers, which will include employers of frontline workers.
The Company now, however, due to disruption of the audit process caused by the Covid-19 crisis, intends to rely on exemptions recently granted by Canadian securities regulatory authorities that allow it to delay the issue of the 2019 Financial Statements, the 2019 MD&A and the 2019 AIF. Without the exemptions, the Company would be required to issue and file its 2019 Annual Financial Statements, 2019 MD&A and 2019 AIF by 30 March 2020. The Company intends to rely on the exemptions to provide its Board of Directors and its recently appointed auditors adequate time to complete the full year audit.
This is the first step to presenting the Aristotle cancer data to the scientific community at large. In a series of studies, we and others have demonstrated that RNA profiles generated from circulating blood can be used to identify patients with a number of conditions, including: lung cancer, bladder cancer, colorectal cancer, osteoarthritis, schizophrenia and bipolar disorder.
StageZero will offer both the serology point-of-care and lab-based PCR tests. StageZero operates a CLIA certified, high complexity laboratory in Richmond, Virginia which is qualified to perform the testing for COVID-19.